8-fluoro-7-methoxy-3,4-dihydronaphthalen-1(2H)-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 8-fluoro-7-methoxy-3,4-dihydronaphthalen-1(2H)-one
• 英文别名: 8-fluoro-7-methoxy-3,4-dihydro-2H-naphthalen-1-one
• 化学式: C₁₁H₁₁FO₂
• mdl: MFCD18648048
• 分子量: 194.206
• InChiKey: MUARQTRVAGGXMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-fluoro-7-methoxy-3,4-dihydronaphthalen-1(2H)-one 在 potassium tert-butylate 、 甲基三苯基溴化膦 作用下， 以 四氢呋喃 为溶剂， 反应 3.5h， 以92.1%的产率得到8-fluoro-7-methoxy-1-methylene-1,2,3,4-tetrahydronaphthalene
  参考文献：
  名称：

  Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles

  摘要：

  GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique Mechanism leading to :little risk of hypoglycemia. We recently reported the discovery of AM-1638 (2), a potent full agonist. GPR40. In this report, we present the discovery Of GPR40 full agonists containing conformationally constrained tricyclic spirocycles and their structure- activity relationships leading to More potent agonists such as AM-5262 (26) with improved rat PK profile and general selectivity profile. AM-5262 enhanced glucose stimulated insulin secretion (mouse and human islets) and improved glucose homeostasis in vivo (OGTT in HF/STZ mice) when compared to AM-1638.,

  DOI：

  10.1021/ml300427u
• 作为产物：
  描述：

  7-甲氧基-1-萘满酮 在 1-fluoro-4-hydroxy-1,4-diazoniabicyclo[2,2,2]octane-1,4-bis(tetrafluoroborate) 作用下， 以 乙腈 为溶剂， 以57%的产率得到8-fluoro-7-methoxy-3,4-dihydronaphthalen-1(2H)-one
  参考文献：
  名称：

  使用 1-fluoro-4-hydroxy-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) 直接氟化芳族酮的溶剂

  摘要：

  芳基烷基酮与 1-fluoro-4-hydroxy-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (AccufluorTM NFTh) 在甲醇中的反应导致选择性和几乎定量地形成相应的 α-氟酮，而在乙腈中，活化的芳环发生排他性的氟官能化。

  DOI：

  10.1039/b003488f

文献信息

• Solvent directing immediate fluorination of aromatic ketones using 1-fluoro-4-hydroxy-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate)
  作者：Stojan Stavber、Marjan Jereb、Marko Zupan

  DOI：10.1039/b003488f

  日期：——

  Reactions of aryl alkyl ketones with 1-fluoro-4-hydroxy-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (AccufluorTM NFTh) in methanol result in selective and almost quantitative formation of the corresponding α-fluoroketones, while in acetonitrile exclusive fluorofunctionalisation of the activated aromatic ring take place.

  芳基烷基酮与 1-fluoro-4-hydroxy-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (AccufluorTM NFTh) 在甲醇中的反应导致选择性和几乎定量地形成相应的 α-氟酮，而在乙腈中，活化的芳环发生排他性的氟官能化。
• SPIROCYCLIC GPR40 MODULATORS
  申请人：Brown Sean P.

  公开号：US20110190330A1

  公开（公告）日：2011-08-04

  The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I′A or I′B: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

  本发明提供了一些化合物，例如用于治疗受试者的代谢性疾病。这些化合物具有一般式IA、IB、I′A或I′B，其中变量的定义在此处提供。本发明还提供了包括这些化合物的组合物，以及使用这些化合物制备药物和治疗代谢性疾病（例如2型糖尿病）的方法。
• [EN] SPIROCYCLIC GPR40 MODULATORS<br/>[FR] MODULATEURS SPIROCYCLIQUES DE GPR40
  申请人：AMGEN INC

  公开号：WO2010045258A3

  公开（公告）日：2010-07-01
• US8748462B2
  申请人：——

  公开号：US8748462B2

  公开（公告）日：2014-06-10
• Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles
  作者：Yingcai Wang、Jiwen (Jim) Liu、Paul J. Dransfield、Liusheng Zhu、Zhongyu Wang、Xiaohui Du、Xianyun Jiao、Yongli Su、An-rong Li、Sean P. Brown、Annie Kasparian、Marc Vimolratana、Ming Yu、Vatee Pattaropong、Jonathan B. Houze、Gayathri Swaminath、Thanhvien Tran、Khanh Nguyen、Qi Guo、Jane Zhang、Run Zhuang、Frank Li、Lynn Miao、Michael D. Bartberger、Tiffany L. Correll、David Chow、Simon Wong、Jian Luo、Daniel C.-H. Lin、Julio C. Medina

  DOI：10.1021/ml300427u

  日期：2013.6.13

  GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique Mechanism leading to :little risk of hypoglycemia. We recently reported the discovery of AM-1638 (2), a potent full agonist. GPR40. In this report, we present the discovery Of GPR40 full agonists containing conformationally constrained tricyclic spirocycles and their structure- activity relationships leading to More potent agonists such as AM-5262 (26) with improved rat PK profile and general selectivity profile. AM-5262 enhanced glucose stimulated insulin secretion (mouse and human islets) and improved glucose homeostasis in vivo (OGTT in HF/STZ mice) when compared to AM-1638.,